Work

Mepolizumab use and glucocorticoid-free remission in eosinophilic granulomatosis with polyangiitis

Year: 2026
Type: article
Study design: Observational Study
Abstract: Objectives To identify clinical characteristics and treatment-related factors associated with glucocorticoid (GC)-free remission in eosinophilic granulomatosis with polyangiitis (EGPA). Methods We retrospectively analyzed patients with EGPA who were treated at our hospital between May 2005 and December 2025. GC-free remission was defined as maintaining a Birmingham Vasculitis Activity Score (BVAS) of 0 for at least 3 months after GC discontinuation. Factors associated with GC-free remission were evaluated using multivariable Cox regression, with mepolizumab (MEP) exposure treated as a time-dependent covariate. Patients who started MEP within one month of GC initiation or dose escalation were defined as the early MEP group. Results A total of 58 patients were included. Forty patients were women (68.9%), and 15 were MPO-ANCA positive (25.9%). Twenty-three patients (39.7%) received pulse GC therapy, and 35 (60.3%) received MEP. During follow-up, 23 patients (39.7%) achieved GC-free remission. MEP use was more frequent among patients who achieved GC-free remission (91.3% vs. 40.0%, p<0.01) and was independently associated with GC-free remission (HR 37.65, 95% CI 8.32–170.27; p<0.001). In patients who achieved GC-free remission, the mean time to remission was shorter in the early MEP group than in the non-early group (462 ± 227 vs. 723 ± 113 days, p = 0.03). Conclusion MEP use was independently associated with GC-free remission in EGPA. Among patients who achieved GC-free remission, earlier MEP initiation was associated with a shorter observed time to GC-free remission.
Language: English
Subfield: Rheumatology
Field: Medicine
Open Access status: gold
Estimated APC paid: $3,801
OpenAlex ID: W7235553598
FWCI:
Cites: 17
Cited by:
Related to: 10
Parts: 1